Market Overview 2025-2033
The Europe medical cannabis market size reached USD 2,586.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 12,652.9 Million by 2033, exhibiting a growth rate (CAGR) of 18.33% during 2025-2033. The market is growing due to increasing legalization, rising medical applications, and expanding research initiatives. Innovations in product development, regulatory support, and patient demand are driving expansion, making it a dynamic and evolving industry.
Key Market Highlights:
✔️ Rapid market growth driven by increasing legalization and acceptance of cannabis for medical use
✔️ Rising demand for cannabis-based treatments in pain management, neurology, and oncology
✔️ Expanding research and investment in pharmaceutical-grade cannabis production and innovation
Request for a sample copy of the report: https://www.imarcgroup.com/europe-medical-cannabis-market/requestsample
Europe Medical Cannabis Market Trends and Drivers:
The European medical cannabis market is growing rapidly due to new regulations. Countries like Germany, the UK, and Italy have made it easier to approve cannabis-based medicines. This change allows patients to access treatments faster. Germany’s 2024 decision to reclassify cannabis as a non-narcotic for certain medical uses was crucial. It cut down on the red tape for getting prescriptions. This shift has led to partnerships between multinational pharmaceutical companies and local growers. They are working together to meet the rising demand. However, some Eastern European countries are slower to adopt patient-focused regulations.
This creates uneven market conditions. Still, the overall trend is moving toward unified regulations. This is helping to create a more connected European market. It is expected to grow at a rate of 22.3% per year until 2030. Patient demand for medical cannabis in Europe is rising fast. This is due to its effectiveness in treating chronic pain, epilepsy, and anxiety. In 2024, more than 35% of prescriptions in France and Spain were for neuropathic pain relief. This shows that healthcare providers are increasingly accepting cannabis. Aging populations and awareness of opioid alternatives also drive this trend.
For example, the UK’s National Health Service (NHS) reported a 40% increase in cannabis-based prescriptions for nausea from chemotherapy. However, reimbursement issues and limited physician training slow down wider use. Startups like *Cannify* and *Algea Care* are filling these gaps. They use telehealth platforms to educate clinicians and consult with patients, improving access in both rural and urban areas.
The European market faces strong competition. Canadian and local producers are fighting for control. In 2024, Aurora Cannabis and Tilray expanded their presence by buying German and Portuguese cultivation sites. They aim to benefit from cost-effective production and EU-GMP certification. Meanwhile, local companies like Demecan and Cantourage are creating strain-specific products for European patients. These include low-THC options for daytime use.
Private equity investments jumped to €480 million in 2024. This funding supports research for new delivery methods, such as sublingual strips and metered-dose inhalers. The increased investment is speeding up clinical trials. Over 15 studies are currently happening in Europe to test cannabis’s effectiveness for PTSD and multiple sclerosis.
The Europe medical cannabis market is changing fast. This change comes from scientific progress, new consumer views, and industry mergers. In 2024, a major event was the European Medicines Agency (EMA) approving cannabis-derived APIs (active pharmaceutical ingredients) for the EU pharmacopeia. This approval helps standardize quality control and boosts confidence among manufacturers. This regulatory step happened alongside a 28% rise in patient registries, reaching 310,000 active users by Q3 2024. Germany is still the largest market, making up 45% of regional revenue. Meanwhile, emerging markets like Poland and Greece are growing quickly, thanks to easier import rules.
The industry is shifting toward sustainability. Vertical farming and carbon-neutral practices are now key competitive factors. Companies like Sanity Group and Cellix Bio are teaming up with renewable energy providers. This helps reduce ecological footprints and aligns with the EU’s Green Deal goals. Digital platforms are connecting patients with providers. Blockchain systems ensure product authenticity, while AI analytics improve dosing regimens. Looking ahead, market growth will depend on fixing reimbursement issues and enhancing clinical education. With 2024 as a turning point for regulatory and commercial innovation, Europe is set to lead in medical cannabis research and application by 2030.
Europe Medical Cannabis Market Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe medical cannabis market forecast. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Study Period:
Base Year: 2024
Historical Year: 2019-2024
Forecast Year: 2025-2033
Breakup by Species:
- Indica
- Sativa
- Hybrid
Breakup by Derivative:
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Breakup by Application:
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
Breakup by End Use:
- Pharmaceutical Industry
- Research and Development Centers
- Others
Breakup by Route of Administration:
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
Breakup by Country:
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
Competitive Landscape:
The market research report offers an in-depth analysis of the competitive landscape, covering market structure, key player positioning, top winning strategies, a competitive dashboard, and a company evaluation quadrant. Additionally, detailed profiles of all major companies are included.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
